https://ir.fibrobiologics.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_14a954ff2903678ce9699bf59a0e1fd9/fibrobiologics/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.fibrobiologics.com/news-events/press-releases/detail/110/fibrobiologics-announces-closing-of-3-million-public-offering Thu, 02 Apr 26 16:01:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/110/fibrobiologics-announces-closing-of-3-million-public-offering https://ir.fibrobiologics.com/news-events/press-releases/detail/109/fibrobiologics-announces-pricing-of-3-million-public-offering Tue, 31 Mar 26 20:00:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/109/fibrobiologics-announces-pricing-of-3-million-public-offering https://ir.fibrobiologics.com/news-events/press-releases/detail/108/fibrobiologics-announces-successful-manufacturing-of-cywc628-drug-product-to-support-upcoming-diabetic-foot-ulcer-clinical-trial Tue, 31 Mar 26 16:15:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/108/fibrobiologics-announces-successful-manufacturing-of-cywc628-drug-product-to-support-upcoming-diabetic-foot-ulcer-clinical-trial https://ir.fibrobiologics.com/news-events/press-releases/detail/107/fibrobiologics-announces-reverse-stock-split-to-regain-compliance-with-nasdaqs-bid-price-requirement Wed, 25 Mar 26 16:30:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/107/fibrobiologics-announces-reverse-stock-split-to-regain-compliance-with-nasdaqs-bid-price-requirement https://ir.fibrobiologics.com/news-events/press-releases/detail/106/fibrobiologics-announces-advances-in-burn-treatment-using-proprietary-fibroblast-spheroid-technology Thu, 12 Mar 26 08:30:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/106/fibrobiologics-announces-advances-in-burn-treatment-using-proprietary-fibroblast-spheroid-technology https://ir.fibrobiologics.com/news-events/press-releases/detail/105/fibrobiologics-completes-site-onboarding-for-phase-12-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers Thu, 05 Mar 26 08:30:00 -0500 https://ir.fibrobiologics.com/news-events/press-releases/detail/105/fibrobiologics-completes-site-onboarding-for-phase-12-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers https://ir.fibrobiologics.com/news-events/press-releases/detail/104/fibrobiologics-inc-announces-issuance-of-u-s-patent-covering-fibroblast-cell-therapy-for-the-treatment-of-osteoporosis Mon, 02 Mar 26 08:30:00 -0500 https://ir.fibrobiologics.com/news-events/press-releases/detail/104/fibrobiologics-inc-announces-issuance-of-u-s-patent-covering-fibroblast-cell-therapy-for-the-treatment-of-osteoporosis https://ir.fibrobiologics.com/news-events/press-releases/detail/103/fibrobiologics-to-present-at-the-bio-investment-growth-summit Thu, 26 Feb 26 08:30:00 -0500 https://ir.fibrobiologics.com/news-events/press-releases/detail/103/fibrobiologics-to-present-at-the-bio-investment-growth-summit https://ir.fibrobiologics.com/news-events/press-releases/detail/102/fibrobiologicsreportsfull-year-2025-financial-resultsand-provides-corporate-update Tue, 24 Feb 26 16:30:00 -0500 https://ir.fibrobiologics.com/news-events/press-releases/detail/102/fibrobiologicsreportsfull-year-2025-financial-resultsand-provides-corporate-update https://ir.fibrobiologics.com/news-events/press-releases/detail/101/fibrobiologics-granted-extension-by-nasdaq-to-regain-compliance Mon, 23 Feb 26 08:30:00 -0500 https://ir.fibrobiologics.com/news-events/press-releases/detail/101/fibrobiologics-granted-extension-by-nasdaq-to-regain-compliance